Effects of preoperative radiotherapy on survival of patients with stage II and III esophageal squamous cell carcinoma: A population-based study
The impact of preoperative radiotherapy (PRT) on survival in patients with stage II and III esophageal squamous cell carcinoma (ESCC) remains controversial. The aim of this study was to explore the effect of PRT on survival of these patients.Patients with stage II and III ESCC who underwent chemothe...
Gespeichert in:
| Veröffentlicht in: | Medicine (Baltimore) 2021-10, Vol.100 (41), p.e27345-e27345 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e27345 |
|---|---|
| container_issue | 41 |
| container_start_page | e27345 |
| container_title | Medicine (Baltimore) |
| container_volume | 100 |
| creator | Dong, Jing Shen, Wenbin Du, Xingyu Zhu, Shuchai |
| description | The impact of preoperative radiotherapy (PRT) on survival in patients with stage II and III esophageal squamous cell carcinoma (ESCC) remains controversial. The aim of this study was to explore the effect of PRT on survival of these patients.Patients with stage II and III ESCC who underwent chemotherapy ± PRT were identified and retrieved from the SEER database from 2010 to 2015. Cox regression analysis was used to identify independent prognostic factors in patients. Subgroup analysis stratified by T stage and N stage was performed. Kaplan-Meier survival analysis was performed to assess disease specific survival (DSS).A total of 1160 patients were retrieved, of whom 289 (24.9%) underwent PRT plus chemotherapy, and 871 (75.1%) did not receive PRT. In multivariate analysis, PRT plus chemotherapy was a favorable prognostic factor for patients with stage T2 (hazard ratio [HR], 0.364, 95% CI, 0.202-0.658; P |
| doi_str_mv | 10.1097/MD.0000000000027345 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8519226</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2593596578</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3556-d6bee5de89ca625ca1b9b249634b073bd7ade604278e9289f8f03c34afd62bc83</originalsourceid><addsrcrecordid>eNpdkU1v1DAQhi0EokvhFyAhH7mk-NsxB6SqLbBSKy5wthx70gSycWonu9pfwV_G2y3lw5eRx8-8M-MXodeUnFFi9LubyzPy5zDNhXyCVlRyVUmjxFO0KllZaaPFCXqR83dCKNdMPEcnXGhOKVEr9POqbcHPGccWTwniBMnN_RZwcqGPc1eu0x7HEeclbfutG-7BgsBYinb93OE8u1vA6zV2YyhhjSHHqSu5Aue7xW3ikrGHYcDeJd-PcePe43M8xWkZilAcq8ZlCEVnCfuX6FnrhgyvHuIp-vbx6uvF5-r6y6f1xfl15bmUqgqqAZABauOdYtI72piGCaO4aIjmTdAugCKC6RoMq01bt4R7LlwbFGt8zU_Rh6PutDQbCL6sk9xgp9RvXNrb6Hr778vYd_Y2bm0tqWFMFYG3DwIp3i2QZ7vp82FLN0JZ2DJpeLFB6kMvfkR9ijknaB_bUGIPVtqbS_u_laXqzd8TPtb89q4A4gjs4jBDyj-GZQfJduXf5-5eT2rDKkZYwakk1SGl-C_IW60V</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2593596578</pqid></control><display><type>article</type><title>Effects of preoperative radiotherapy on survival of patients with stage II and III esophageal squamous cell carcinoma: A population-based study</title><source>PubMed (Medline)</source><source>IngentaConnect Backfiles</source><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Alma/SFX Local Collection</source><source>EZB Electronic Journals Library</source><source>Wolters Kluwer Open Access</source><creator>Dong, Jing ; Shen, Wenbin ; Du, Xingyu ; Zhu, Shuchai</creator><creatorcontrib>Dong, Jing ; Shen, Wenbin ; Du, Xingyu ; Zhu, Shuchai</creatorcontrib><description>The impact of preoperative radiotherapy (PRT) on survival in patients with stage II and III esophageal squamous cell carcinoma (ESCC) remains controversial. The aim of this study was to explore the effect of PRT on survival of these patients.Patients with stage II and III ESCC who underwent chemotherapy ± PRT were identified and retrieved from the SEER database from 2010 to 2015. Cox regression analysis was used to identify independent prognostic factors in patients. Subgroup analysis stratified by T stage and N stage was performed. Kaplan-Meier survival analysis was performed to assess disease specific survival (DSS).A total of 1160 patients were retrieved, of whom 289 (24.9%) underwent PRT plus chemotherapy, and 871 (75.1%) did not receive PRT. In multivariate analysis, PRT plus chemotherapy was a favorable prognostic factor for patients with stage T2 (hazard ratio [HR], 0.364, 95% CI, 0.202-0.658; P < .001), T3 (HR, 0.536, 95% CI, 0.413-0.695; P < .001) and T4 (HR, 0.318, 95% CI, 0.125-0.805; P = .016), but PRT plus chemotherapy was not statistically significant on DSS in patients with T1 disease (HR, 0.556, 95% CI, 0.262-1.179; P = .126). All 3 different N stages (N0, N1, and N2 + N3) were statistically significant (P < .05) in chemotherapy with or without PRT.In conclusion, patients with stage II and III ESCC at the T2-T4 stage gained significant survival benefit from PRT plus chemotherapy.</description><identifier>ISSN: 0025-7974</identifier><identifier>EISSN: 1536-5964</identifier><identifier>DOI: 10.1097/MD.0000000000027345</identifier><identifier>PMID: 34731106</identifier><language>eng</language><publisher>United States: Lippincott Williams & Wilkins</publisher><subject>Adult ; Aged ; Esophageal Neoplasms - mortality ; Esophageal Neoplasms - pathology ; Esophageal Neoplasms - therapy ; Esophageal Squamous Cell Carcinoma - mortality ; Esophageal Squamous Cell Carcinoma - pathology ; Esophageal Squamous Cell Carcinoma - therapy ; Female ; Humans ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Neoadjuvant Therapy - methods ; Neoplasm Staging ; Observational Study ; Proportional Hazards Models ; Radiotherapy - statistics & numerical data ; Retrospective Studies ; SEER Program</subject><ispartof>Medicine (Baltimore), 2021-10, Vol.100 (41), p.e27345-e27345</ispartof><rights>Lippincott Williams & Wilkins</rights><rights>Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.</rights><rights>Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc. 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c3556-d6bee5de89ca625ca1b9b249634b073bd7ade604278e9289f8f03c34afd62bc83</cites><orcidid>0000-0001-8077-9859</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8519226/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8519226/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34731106$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dong, Jing</creatorcontrib><creatorcontrib>Shen, Wenbin</creatorcontrib><creatorcontrib>Du, Xingyu</creatorcontrib><creatorcontrib>Zhu, Shuchai</creatorcontrib><title>Effects of preoperative radiotherapy on survival of patients with stage II and III esophageal squamous cell carcinoma: A population-based study</title><title>Medicine (Baltimore)</title><addtitle>Medicine (Baltimore)</addtitle><description>The impact of preoperative radiotherapy (PRT) on survival in patients with stage II and III esophageal squamous cell carcinoma (ESCC) remains controversial. The aim of this study was to explore the effect of PRT on survival of these patients.Patients with stage II and III ESCC who underwent chemotherapy ± PRT were identified and retrieved from the SEER database from 2010 to 2015. Cox regression analysis was used to identify independent prognostic factors in patients. Subgroup analysis stratified by T stage and N stage was performed. Kaplan-Meier survival analysis was performed to assess disease specific survival (DSS).A total of 1160 patients were retrieved, of whom 289 (24.9%) underwent PRT plus chemotherapy, and 871 (75.1%) did not receive PRT. In multivariate analysis, PRT plus chemotherapy was a favorable prognostic factor for patients with stage T2 (hazard ratio [HR], 0.364, 95% CI, 0.202-0.658; P < .001), T3 (HR, 0.536, 95% CI, 0.413-0.695; P < .001) and T4 (HR, 0.318, 95% CI, 0.125-0.805; P = .016), but PRT plus chemotherapy was not statistically significant on DSS in patients with T1 disease (HR, 0.556, 95% CI, 0.262-1.179; P = .126). All 3 different N stages (N0, N1, and N2 + N3) were statistically significant (P < .05) in chemotherapy with or without PRT.In conclusion, patients with stage II and III ESCC at the T2-T4 stage gained significant survival benefit from PRT plus chemotherapy.</description><subject>Adult</subject><subject>Aged</subject><subject>Esophageal Neoplasms - mortality</subject><subject>Esophageal Neoplasms - pathology</subject><subject>Esophageal Neoplasms - therapy</subject><subject>Esophageal Squamous Cell Carcinoma - mortality</subject><subject>Esophageal Squamous Cell Carcinoma - pathology</subject><subject>Esophageal Squamous Cell Carcinoma - therapy</subject><subject>Female</subject><subject>Humans</subject><subject>Kaplan-Meier Estimate</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neoadjuvant Therapy - methods</subject><subject>Neoplasm Staging</subject><subject>Observational Study</subject><subject>Proportional Hazards Models</subject><subject>Radiotherapy - statistics & numerical data</subject><subject>Retrospective Studies</subject><subject>SEER Program</subject><issn>0025-7974</issn><issn>1536-5964</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkU1v1DAQhi0EokvhFyAhH7mk-NsxB6SqLbBSKy5wthx70gSycWonu9pfwV_G2y3lw5eRx8-8M-MXodeUnFFi9LubyzPy5zDNhXyCVlRyVUmjxFO0KllZaaPFCXqR83dCKNdMPEcnXGhOKVEr9POqbcHPGccWTwniBMnN_RZwcqGPc1eu0x7HEeclbfutG-7BgsBYinb93OE8u1vA6zV2YyhhjSHHqSu5Aue7xW3ikrGHYcDeJd-PcePe43M8xWkZilAcq8ZlCEVnCfuX6FnrhgyvHuIp-vbx6uvF5-r6y6f1xfl15bmUqgqqAZABauOdYtI72piGCaO4aIjmTdAugCKC6RoMq01bt4R7LlwbFGt8zU_Rh6PutDQbCL6sk9xgp9RvXNrb6Hr778vYd_Y2bm0tqWFMFYG3DwIp3i2QZ7vp82FLN0JZ2DJpeLFB6kMvfkR9ijknaB_bUGIPVtqbS_u_laXqzd8TPtb89q4A4gjs4jBDyj-GZQfJduXf5-5eT2rDKkZYwakk1SGl-C_IW60V</recordid><startdate>20211015</startdate><enddate>20211015</enddate><creator>Dong, Jing</creator><creator>Shen, Wenbin</creator><creator>Du, Xingyu</creator><creator>Zhu, Shuchai</creator><general>Lippincott Williams & Wilkins</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-8077-9859</orcidid></search><sort><creationdate>20211015</creationdate><title>Effects of preoperative radiotherapy on survival of patients with stage II and III esophageal squamous cell carcinoma: A population-based study</title><author>Dong, Jing ; Shen, Wenbin ; Du, Xingyu ; Zhu, Shuchai</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3556-d6bee5de89ca625ca1b9b249634b073bd7ade604278e9289f8f03c34afd62bc83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Esophageal Neoplasms - mortality</topic><topic>Esophageal Neoplasms - pathology</topic><topic>Esophageal Neoplasms - therapy</topic><topic>Esophageal Squamous Cell Carcinoma - mortality</topic><topic>Esophageal Squamous Cell Carcinoma - pathology</topic><topic>Esophageal Squamous Cell Carcinoma - therapy</topic><topic>Female</topic><topic>Humans</topic><topic>Kaplan-Meier Estimate</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neoadjuvant Therapy - methods</topic><topic>Neoplasm Staging</topic><topic>Observational Study</topic><topic>Proportional Hazards Models</topic><topic>Radiotherapy - statistics & numerical data</topic><topic>Retrospective Studies</topic><topic>SEER Program</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dong, Jing</creatorcontrib><creatorcontrib>Shen, Wenbin</creatorcontrib><creatorcontrib>Du, Xingyu</creatorcontrib><creatorcontrib>Zhu, Shuchai</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Medicine (Baltimore)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dong, Jing</au><au>Shen, Wenbin</au><au>Du, Xingyu</au><au>Zhu, Shuchai</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effects of preoperative radiotherapy on survival of patients with stage II and III esophageal squamous cell carcinoma: A population-based study</atitle><jtitle>Medicine (Baltimore)</jtitle><addtitle>Medicine (Baltimore)</addtitle><date>2021-10-15</date><risdate>2021</risdate><volume>100</volume><issue>41</issue><spage>e27345</spage><epage>e27345</epage><pages>e27345-e27345</pages><issn>0025-7974</issn><eissn>1536-5964</eissn><abstract>The impact of preoperative radiotherapy (PRT) on survival in patients with stage II and III esophageal squamous cell carcinoma (ESCC) remains controversial. The aim of this study was to explore the effect of PRT on survival of these patients.Patients with stage II and III ESCC who underwent chemotherapy ± PRT were identified and retrieved from the SEER database from 2010 to 2015. Cox regression analysis was used to identify independent prognostic factors in patients. Subgroup analysis stratified by T stage and N stage was performed. Kaplan-Meier survival analysis was performed to assess disease specific survival (DSS).A total of 1160 patients were retrieved, of whom 289 (24.9%) underwent PRT plus chemotherapy, and 871 (75.1%) did not receive PRT. In multivariate analysis, PRT plus chemotherapy was a favorable prognostic factor for patients with stage T2 (hazard ratio [HR], 0.364, 95% CI, 0.202-0.658; P < .001), T3 (HR, 0.536, 95% CI, 0.413-0.695; P < .001) and T4 (HR, 0.318, 95% CI, 0.125-0.805; P = .016), but PRT plus chemotherapy was not statistically significant on DSS in patients with T1 disease (HR, 0.556, 95% CI, 0.262-1.179; P = .126). All 3 different N stages (N0, N1, and N2 + N3) were statistically significant (P < .05) in chemotherapy with or without PRT.In conclusion, patients with stage II and III ESCC at the T2-T4 stage gained significant survival benefit from PRT plus chemotherapy.</abstract><cop>United States</cop><pub>Lippincott Williams & Wilkins</pub><pmid>34731106</pmid><doi>10.1097/MD.0000000000027345</doi><orcidid>https://orcid.org/0000-0001-8077-9859</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0025-7974 |
| ispartof | Medicine (Baltimore), 2021-10, Vol.100 (41), p.e27345-e27345 |
| issn | 0025-7974 1536-5964 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8519226 |
| source | PubMed (Medline); IngentaConnect Backfiles; MEDLINE; DOAJ Directory of Open Access Journals; Alma/SFX Local Collection; EZB Electronic Journals Library; Wolters Kluwer Open Access |
| subjects | Adult Aged Esophageal Neoplasms - mortality Esophageal Neoplasms - pathology Esophageal Neoplasms - therapy Esophageal Squamous Cell Carcinoma - mortality Esophageal Squamous Cell Carcinoma - pathology Esophageal Squamous Cell Carcinoma - therapy Female Humans Kaplan-Meier Estimate Male Middle Aged Neoadjuvant Therapy - methods Neoplasm Staging Observational Study Proportional Hazards Models Radiotherapy - statistics & numerical data Retrospective Studies SEER Program |
| title | Effects of preoperative radiotherapy on survival of patients with stage II and III esophageal squamous cell carcinoma: A population-based study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-11T16%3A43%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effects%20of%20preoperative%20radiotherapy%20on%20survival%20of%20patients%20with%20stage%20II%20and%20III%20esophageal%20squamous%20cell%20carcinoma:%20A%20population-based%20study&rft.jtitle=Medicine%20(Baltimore)&rft.au=Dong,%20Jing&rft.date=2021-10-15&rft.volume=100&rft.issue=41&rft.spage=e27345&rft.epage=e27345&rft.pages=e27345-e27345&rft.issn=0025-7974&rft.eissn=1536-5964&rft_id=info:doi/10.1097/MD.0000000000027345&rft_dat=%3Cproquest_pubme%3E2593596578%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2593596578&rft_id=info:pmid/34731106&rfr_iscdi=true |